Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service MembersPartnership Represents a Significant Expansion of Company's Commercial

Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members

Partnership Represents a Significant Expansion of Company's Commercial Footprint into the U.S. Government and Defense Health Sectors

KENMORE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (NASDAQ:AIFF) ("Firefly," or the "Company"), today announced a partnership with the Department of War ("DoW") to support the assessment and treatment of active-duty U.S. service members and veterans suffering from Post-Traumatic Stress Disorder ("PTSD") and/or Traumatic Brain Injury ("TBI").

The genesis of this innovative public-private brain health partnership was initial work by the founders of Evoke Neuroscience, Inc. (acquired by Firefly in May 2025) with the U.S. Naval Medical Center Camp Lejeune Family Medicine Residency program. Specific details of the partnership and related programs remain confidential in accordance with applicable agreements.

Addressing a Multi-Billion Dollar Military Mental Health Crisis

PTSD and TBI represent two of the most significant and pervasive health challenges facing the U.S. military. The total excess economic burden of PTSD in the United States has been estimated at $232.2 billion, of which approximately $42.7 billion is attributed directly to the military population.1 In contrast to PTSD, the incidence of TBI is higher among military than civilian populations, in part because of the physical demands of military service and the potentially dangerous activities associated with military operations and training.2 According to the RAND Corporation, more than 444,300 U.S. service members were diagnosed with at least one TBI between 2000 and 2021.3

Despite the scale of this public and military health burden, objective, biomarker-driven diagnostic tools have remained largely absent from standard care — a gap that Firefly's EEG/ERP technology is intended to help address.

FDA-Cleared AI Technology Supporting DoW Programs

Firefly's FDA 510(k)-cleared, AI-powered EEG/ERP platform is being utilized across related DoW programs, providing military healthcare providers with objective, quantitative neurological data intended to support more precise diagnosis, individualized treatment planning, and measurable outcomes tracking. The platform is non-invasive, scalable across both clinical and operational environments, and designed for real-world deployment at scale. The DoW partnership represents a potentially significant channel for Firefly's commercial strategy, expanding the Company's footprint into the U.S. government and defense health sectors.